Patrick W. Serruys

JAN 2025RoyenEuroIntervention

Myval THV matches SAPIEN and Evolut for 30-day VARC-3 composite outcomes.

In this powered, predefined substudy of the LANDMARK trial, the novel balloon-expandable Myval THV series demonstrated non-inferiority at 30 days compared individually to both the SAPIEN and Evolut THV series for composite safety and effectiveness in patients with severe symptomatic native aortic stenosis.

MAY 2024BaumbachThe Lancet

Myval THV proves non-inferior to contemporary valves, matching 30-day outcomes within ~2 percentage points.

Myval THV series offers a non-inferior TAVR option in severe aortic stenosis; extends randomized evidence for next-generation valves versus Sapien and Evolut.

JAN 2016MilojevicJournal of the American College of Cardiology

PCI increases 5-year cardiac death ~55% vs. CABG, despite similar all-cause mortality.

May favor CABG to lower cardiac death in complex CAD; leaves open all-cause mortality impact and broader adoption.

MAR 2021BrugalettaJournal of the American College of Cardiology

Everolimus-eluting stents cut 10-year composite events ~19% vs. bare-metal stents in STEMI.

Supports EES over BMS for 10-year POCE/DOCE in STEMI PCI; confirms early TLR reduction sustains superiority without late divergence.

OCT 2024TobeEuropean Heart Journal

Sirolimus-coated balloons lower post-procedure microcirculatory resistance compared to paclitaxel-coated balloons.

Both sirolimus- and paclitaxel-coated balloons increase angiography-derived microcirculatory resistance immediately after treatment in small coronary vessels, but crystalline paclitaxel-coated balloons result in significantly higher post-procedure resistance and a greater rate of coronary microvascular dysfunction compared to sirolimus-coated balloons.

QFR-guided PCI reduces 3-year MACE ~35% vs angiography-guided PCI in multivessel disease.

In this prespecified secondary analysis of the FAVOR III China trial, QFR-guided PCI significantly reduced 3-year MACE compared to angiography-guided PCI in patients with multivessel disease, with consistent directional benefit regardless of MVD status.

Intraclass correlation coefficient values between CarnaLife Holo and 3mensio Structural Heart all exceeded 0.99 for annulus area measurements, with high interobserver agreement (p=0.906) and no significant difference in membranous septum areas across the three patient cohorts (p=0.1640).

3D holography may enable precise membranous septum assessment in TAVI; leaves open whether it reduces pacemaker implantation.

NOV 2025SerruysJournal of the American College of Cardiology

Myval THV was noninferior to contemporary THVs for the 1-year composite of all-cause mortality, strokes, or valve-related hospitalizations (freedom from events 87.0% vs 86.9%, p<0.0001).

The novel balloon-expandable Myval THV series provides comparable 1-year clinical efficacy to established contemporary THVs in patients with severe symptomatic aortic stenosis.

SYNTAX Score II 2020 predicts 5-year mortality and identifies patients with survival benefit from CABG.

External validation in a Japanese registry confirms the SYNTAX Score II 2020 accurately predicts 5-year mortality and can aid in identifying which patients with complex coronary disease derive a clear survival benefit from CABG over PCI.

APR 2017RuizJournal of the American College of Cardiology

Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis

Standardizes trial endpoints and grading for paravalvular leak closure devices; extends VARC framework to guide future device evaluation.

Long-Term Mortality After PCI or CABG for Left Main Stem Disease

Role of the endothelium in modulating neointimal formationVasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions

Drug-eluting stents show similar 30-day stent thrombosis rates compared to bare-metal stents.

Supports similar real-world 30-day stent thrombosis safety; leaves open confirmation versus randomized trials in unrestricted populations.

OCT 2010HolmesJournal of the American College of Cardiology

Stent thrombosis prevention research targets genomics and antiplatelet variability to identify high-risk patients.

Antiplatelet therapies retain their established preventive role; leaves open refinement via genomics and predictive factors in future studies.

Angio-IMR methods fail to accurately identify coronary microvascular dysfunction compared with invasive PW-IMR.

Angio-IMR methods should not yet replace invasive PW-IMR; leaves open refinement and prospective validation of angiography-based microvascular indices.

Failing to achieve QCA device success links to ~3-point higher 1-year LOCE.

Operator visual assessment overestimates device success; core lab QCA flags higher-risk lesions and leaves standardized adjudication open for trial endpoints.

Stepwise DAPT de-escalation shows no benefit over standard DAPT for NACE in bifurcation ACS.

Similar NACE with less major bleeding in subgroup; hypothesis-generating and should not yet change practice in ACS bifurcation lesions.

SEP 29GiacobbeJournal of the American Heart Association

Transcatheter aortic valve implantation had a 10.2% all-cause mortality rate at 12 months, with acute kidney injury, bleeding, and periprocedural stroke associated with higher mortality.

TAVI demonstrates high procedural success but carries non-negligible complication rates under the updated VARC-3 criteria, with acute kidney injury, bleeding, and non-structural valve dysfunction predicting higher mortality.